Last Updated : June 29, 2023
Details
FilesProject Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Rapid Review
Project Number:
RC1484-000
Question
- What is the clinical effectiveness of alternative treatments to IV Immunoglobulin (IVIG) compared to IVIG or placebo for idiopathic inflammatory myopathies?
- What is the safety of alternative treatments to IVIG compared to IVIG or placebo for idiopathic inflammatory myopathies?
- What are the evidence-based guidelines regarding alternative treatments to IVIG for idiopathic inflammatory myopathies?
Key Message
We did not find any evidence regarding the clinical effectiveness and safety of alternative treatments to IV Immunoglobulin (IVIG) compared to IVIG or placebo for idiopathic inflammatory myopathies (IIM) that met our inclusion criteria for this review. Three evidence-based guidelines provide recommendations regarding IVIG and other drugs to manage IIM. However, we did not find any recommendations regarding alternative treatments to IVIG specifically. Rituximab may be considered as another option to IVIG to treat IIM-related skeletal muscle inflammation (1 guideline) or skin manifestations (1 guideline) resistant to treatment with steroids. In juvenile IIM, rituximab or IVIG can be used as adjunct care in case of treatment failure.
Files
Last Updated : June 29, 2023